Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide

Documenti analoghi

• Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
  di: Alice Y. Y. Cheng, et al.
  Pubblicazione: (2025)
• Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
  di: Brandon K. Bergman, et al.
  Pubblicazione: (2025)
• Prevalence of complications and co‐morbidities in males and females with obesity: Real‐world insights from claims data analysis
  di: Jay P. Bae, et al.
  Pubblicazione: (2024)
• Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
  di: Man Tang, et al.
  Pubblicazione: (2025)
• Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
  di: Andreea Ciudin, et al.
  Pubblicazione: (2026)